Citadel Advisors’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-19,400
| Closed | -$278K | – | 13260 |
|
|
2025
Q3 | $278K | Sell |
19,400
-5,200
| -21% | -$71.2K | ﹤0.01% | 10549 |
|
|
2025
Q2 | $302K | Buy |
24,600
+1,300
| +6% | +$18.9K | ﹤0.01% | 9810 |
|
|
2025
Q1 | $512K | Buy |
23,300
+1,600
| +7% | +$37.6K | ﹤0.01% | 8421 |
|
|
2024
Q4 | $492K | Buy |
21,700
+7,100
| +49% | +$155K | ﹤0.01% | 8581 |
|
|
2024
Q3 | $265K | Buy |
14,600
+13,900
| +1,986% | +$322K | ﹤0.01% | 9569 |
|
|
2024
Q2 | $20.4K | Sell |
700
-1,300
| -65% | -$38.6K | ﹤0.01% | 12620 |
|
|
2024
Q1 | $70.9K | Sell |
2,000
-1,200
| -38% | -$48K | ﹤0.01% | 11804 |
|
|
2023
Q4 | $139K | Buy |
+3,200
| New | +$126K | ﹤0.01% | 10499 |
|
|
2023
Q3 | – | Sell |
-4,300
| Closed | -$177K | – | 14637 |
|
|
2023
Q2 | $177K | Sell |
4,300
-2,500
| -37% | -$120K | ﹤0.01% | 10076 |
|
|
2023
Q1 | $390K | Buy |
6,800
+2,400
| +55% | +$135K | ﹤0.01% | 8819 |
|
|
2022
Q4 | $247K | Buy |
+4,400
| New | +$224K | ﹤0.01% | 9720 |
|
|
2022
Q2 | – | Sell |
-4,900
| Closed | -$315K | – | 13399 |
|
|
2022
Q1 | $315K | Buy |
+4,900
| New | +$323K | ﹤0.01% | 10486 |
|
|
2021
Q3 | – | Sell |
-5,000
| Closed | -$341K | – | 14180 |
|
|
2021
Q2 | $341K | Buy |
+5,000
| New | +$354K | ﹤0.01% | 10960 |
|
|
2020
Q4 | – | Sell |
-6,300
| Closed | -$297K | – | 11181 |
|
|
2020
Q3 | $297K | Sell |
6,300
-1,100
| -15% | -$52.3K | ﹤0.01% | 8145 |
|
|
2020
Q2 | $348K | Buy |
+7,400
| New | +$364K | ﹤0.01% | 7673 |
|
|
2020
Q1 | – | Sell |
-4,700
| Closed | -$274K | – | 9838 |
|
|
2019
Q4 | $274K | Hold |
4,700
| – | – | ﹤0.01% | 7731 |
|
|
2019
Q3 | $282K | Sell |
4,700
-1,700
| -27% | -$101K | ﹤0.01% | 7644 |
|
|
2019
Q2 | $357K | Sell |
6,400
-400
| -6% | -$20.6K | ﹤0.01% | 7308 |
|
|
2019
Q1 | $379K | Buy |
+6,800
| New | +$346K | ﹤0.01% | 7250 |
|
|
2018
Q4 | – | Sell |
-9,800
| Closed | -$646K | – | 9400 |
|
|
2018
Q3 | $646K | Buy |
9,800
+500
| +5% | +$31.1K | ﹤0.01% | 6288 |
|
|
2018
Q2 | $599K | Buy |
9,300
+2,600
| +39% | +$161K | ﹤0.01% | 6077 |
|
|
2018
Q1 | $371K | Buy |
+6,700
| New | +$351K | ﹤0.01% | 6393 |
|
|
2016
Q2 | – | Sell |
-6,200
| Closed | -$209K | – | 7044 |
|
|
2016
Q1 | $209K | Buy |
6,200
+2,200
| +55% | +$68.5K | ﹤0.01% | 5581 |
|
|
2015
Q4 | $136K | Buy |
4,000
+1,600
| +67% | +$50K | ﹤0.01% | 6328 |
|
|
2015
Q3 | $71K | Sell |
2,400
-12,034
| -83% | -$376K | ﹤0.01% | 7286 |
|
|
2015
Q2 | $397K | Hold |
14,434
| – | – | ﹤0.01% | 5330 |
|
|
2015
Q1 | $364K | Buy |
14,434
+11,988
| +490% | +$283K | ﹤0.01% | 5383 |
|
|
2014
Q4 | $54K | Sell |
2,446
-979
| -29% | -$19.8K | ﹤0.01% | 7132 |
|
|
2014
Q3 | $69K | Buy |
3,425
+245
| +8% | +$4.88K | ﹤0.01% | 6680 |
|
|
2014
Q2 | $61K | Buy |
3,180
+489
| +18% | +$9.11K | ﹤0.01% | 6614 |
|
|
2014
Q1 | $51K | Buy |
2,691
+978
| +57% | +$18.9K | ﹤0.01% | 6767 |
|
|
2013
Q4 | $33K | Buy |
+1,713
| New | +$31.4K | ﹤0.01% | 6241 |
|
|
2013
Q3 | – | Sell |
-2,691
| Closed | -$40K | – | 6781 |
|
|
2013
Q2 | $40K | Buy |
+2,691
| New | +$39.4K | ﹤0.01% | 5774 |
|
Other funds holding IART
RCMNY
PCMI
VPM
VCM
Citadel Advisors's IART Position: Q1 2026 in Review
Citadel Advisors increased its Integra LifeSciences (IART) stake by 86% in Q1 2026, buying an estimated $2.43M and bringing the position to 476,701 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #4520.
Citadel Advisors first reported a position in IART in Q2 2013 and has held it in 42 quarters since. The position peaked at $22.7M in Q1 2017. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.
- Citadel Advisors held 476,701 shares of Integra LifeSciences worth $4.49M as of Q1 2026.
- Citadel Advisors bought 220,894 Integra LifeSciences shares in Q1 2026, an estimated $2.43M.
- Integra LifeSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4520 holding.
- Citadel Advisors first reported a position in Integra LifeSciences in Q2 2013 and has held it in 42 quarters since.
- Citadel Advisors's Integra LifeSciences position peaked at $22.7M in Q1 2017.
- 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.